MVT-602 (other developmental code names RVT-602, TAK-448) is a kisspeptin receptor agonist which is under development for the treatment of female infertility and hypogonadism.

[1][2] It has been found to increase luteinizing hormone levels in premenopausal women.

[2] As of March 2021, MVT-602 is in phase 2 clinical trials for the treatment of female infertility and hypogonadism.

[1] It was also under development for the treatment of prostate cancer, but development for this indication was discontinued.

[1] This drug article relating to the genito-urinary system is a stub.